NCT02558465View on ClinicalTrials.gov

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)

CompletedOBSERVATIONAL

Enrollment

2,540

Participants

Timeline

Start Date

November 13, 2015

Primary Completion Date

April 1, 2021

Study Completion Date

May 31, 2021

Conditions

Venous Thromboembolism

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Treatment parameters following the summary of product characteristics and the physician's decision

Trial Locations (1)

Unknown

Many locations, Multiple Locations

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Bayer

INDUSTRY